Veerhealth Care
- Market cap
- ₹ 100 Cr.
- P/E
- 74.6x
- P/B
- 4.28x
- 52-week range
- 16.7 – 52
- ROE
- 3%
- ROCE
- 7.2%
- Dividend yield
- 0%
- Debt / equity
- 0.2
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Veerhealth Care Limited is an India-based company. The Company is engaged in the business of trading and manufacturing and marketing research-based ayurvedic medicines. The Company operates through the Ayurved Pharma Products segment. It is also engaged in the manufacturing of oral care products. The Company’s product categories include skincare, body care, haircare, fragrances, healthcare, oral care, gifting, combos, and accessories. Its skincare products include creams, lip balm, moisturizing lotion, face packs, and rosewater. Its body care products include bodywash, facewash, handwash and soaps. Its haircare products include hair oil, shampoo, and conditioners. Its fragrances include body mist. Its healthcare products consist of pain relief oil, tablets, syrups, and sanitizers. Its oral care products include toothpaste. It offers various combos, such as Haircare Regime, Bath Ritual, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Veerhealth Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)74.6 against a typical 34.3: pricier than most peers (1st = cheapest).178th of 220
- Sales growth+455.2% against a typical +15.6% from a year earlier.3rd of 197
- Profit growth+412.5% against a typical +18.9% from a year earlier.11th of 160
- Share price, 3 months+15.9% against a typical −0.5%.48th of 200
- Size₹ 100.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).149th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 3 | 2 | 5 | 4 | 6 | 4 | 4 | 7 | 17 | 25 |
| Expenses | 4 | 3 | 3 | 2 | 5 | 4 | 6 | 5 | 3 | 6 | 16 | 23 |
| Operating Profit | 0 | 0 | 0 | −0 | 0 | 0 | −0 | −0 | 1 | 1 | 1 | 2 |
| OPM % | 5.5% | 5.9% | 5% | −1% | 9.3% | 3.9% | −2.9% | −0.7% | 13.3% | 17.1% | 4.4% | 7.7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | −0 | −0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 1 | 0 | 1 |
| Tax % | 13.3% | 17.4% | 443.8% | 20% | 28.6% | 0% | −23.1% | 0% | 25.7% | 18% | 294.4% | 16.9% |
| Net Profit | 0 | 0 | −1 | 0 | 0 | 0 | −0 | 0 | 0 | 0 | −0 | 1 |
| EPS in Rs | 0.2 | 0.1 | −0.28 | 0.06 | 0.15 | 0.04 | −0.05 | 0.12 | 0.13 | 0.2 | −0.18 | 0.62 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 31%
- 5 Years
- 25%
- 3 Years
- 35%
- TTM
- 177%
- 10 Years
- 52%
- 5 Years
- 12%
- 3 Years
- −25%
- TTM
- 157%
- 10 Years
- 22%
- 5 Years
- 60%
- 3 Years
- 32%
- TTM
- —
- 10 Years
- 2%
- 5 Years
- 3%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Veerhealth Care | ₹ 48.90 | ₹ 100 Cr. | 74.6x | 4.3x | 3% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Akash Shah
- Chief Financial Officer
- Ashita Chittora
- Compliance Officer, Company Secretary
- Bhavin Satish Shah
- Managing Director, Whole time Director
- Shruti Akash Shah
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.